A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ia study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of PMG1015 injection in healthy volunteers
Latest Information Update: 10 Nov 2025
At a glance
- Drugs PMG 1015 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
Most Recent Events
- 10 Nov 2025 New trial record